Healthcare Sector

Against its annual contracted value of USD50m supplies for Librela, Syngene has supplied USD94m worth of Librela to Zoetis over the past 13 months, which likely implies that Librela supplies to Zoetis will continue to taper off in CY24 and will present a tough base for Syngene going ahead. Syngene shipped just USD2m worth of Librela in Feb’24 vs USD21/13m in Dec’23/Jan’24 respectively.

The settlement agreement opens the door for Yesafili, a planned biosimilar of Eeylea (aflibercept) injection, to be sold in Canada.

Apollo Hospitals, KIMS, and Fortis Healthcare all declined about 2%.

This approval adds to Strides' list of products in the HIV treatment category through the PEPFAR pathway, totaling 15 products

The product is bioequivalent and therapeutically equivalent to Vascepa (Reference Listed Drug) and will be produced in Bengaluru.

SEBI mandates that promoters cannot hold more than 75% of a company's stake, and Glenmark has until August 2024 to meet this requirement

It was mentioned that at the end of the inspection, a Form 483 was given with one procedural observation.

Tyvalzi™ is designed to treat cerebral ischemic stroke and is a first-in-class drug developed by Pharmazz for potential global use

Bajaj Healthcare's Savli plant is primarily involved in manufacturing Active Pharmaceutical Ingredients (API)

Torrent Pharma's interest stems from its desire to acquire a company with metrics more than 2.3 times its revenue, double its profit, and 1.46 times its market value